195 related articles for article (PubMed ID: 22108522)
21. Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors.
Kothari S; Nelson SP; Wu EQ; Beaulieu N; McHale JM; Dabbous OH
Curr Med Res Opin; 2009 Nov; 25(11):2703-9. PubMed ID: 19775195
[TBL] [Abstract][Full Text] [Related]
22. Association of Proton Pump Inhibitor/Histamine-2 Blocker Use and Ocular Toxoplasmosis: Findings from a Large US National Database.
Conrady CD; Pradeep T; Yu Y; Johnson MW; VanderBeek BL
Ophthalmol Retina; 2023 Mar; 7(3):261-265. PubMed ID: 36058521
[TBL] [Abstract][Full Text] [Related]
23. Proton-Pump Inhibitors and Risk of Calcium Pyrophosphate Deposition in a Population-Based Study.
Liew JW; Peloquin C; Tedeschi SK; Felson DT; Zhang Y; Choi HK; Terkeltaub R; Neogi T
Arthritis Care Res (Hoboken); 2022 Dec; 74(12):2059-2065. PubMed ID: 35245410
[TBL] [Abstract][Full Text] [Related]
24. Proton pump inhibitor use and risk of breast cancer, prostate cancer, and malignant melanoma: An Icelandic population-based case-control study.
Hálfdánarson ÓÖ; Fall K; Ogmundsdottir MH; Lund SH; Steingrímsson E; Ogmundsdottir HM; Zoega H
Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):471-478. PubMed ID: 30565786
[TBL] [Abstract][Full Text] [Related]
25. Use of Proton Pump Inhibitors and Risk of Pancreatic Cancer: A Nationwide Case-Control Study Based on the French National Health Data System (SNDS).
Lassalle M; Le Tri T; Afchain P; Camus M; Kirchgesner J; Zureik M; Dray-Spira R
Cancer Epidemiol Biomarkers Prev; 2022 Mar; 31(3):662-669. PubMed ID: 34937794
[TBL] [Abstract][Full Text] [Related]
26. Proton-pump inhibitor use and the risk for community-acquired pneumonia.
Sarkar M; Hennessy S; Yang YX
Ann Intern Med; 2008 Sep; 149(6):391-8. PubMed ID: 18794558
[TBL] [Abstract][Full Text] [Related]
27. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
Brusselaers N; Wahlin K; Engstrand L; Lagergren J
BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798
[TBL] [Abstract][Full Text] [Related]
28. Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study.
Bradley MC; Hughes CM; Cantwell MM; Napolitano G; Murray LJ
Br J Cancer; 2010 Apr; 102(9):1415-21. PubMed ID: 20372155
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of children and adolescents first prescribed proton pump inhibitors or histamine-2-receptor antagonists: an observational cohort study.
Ruigómez A; Kool-Houweling LMA; García Rodríguez LA; Penning-van Beest FJA; Herings RMC
Curr Med Res Opin; 2017 Dec; 33(12):2251-2259. PubMed ID: 28562108
[TBL] [Abstract][Full Text] [Related]
30. The use of drugs acting on the renin-angiotensin system and the incidence of pancreatic cancer.
Mandilaras V; Bouganim N; Yin H; Asselah J; Azoulay L
Br J Cancer; 2017 Jan; 116(1):103-108. PubMed ID: 27846200
[TBL] [Abstract][Full Text] [Related]
31. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency.
Lam JR; Schneider JL; Zhao W; Corley DA
JAMA; 2013 Dec; 310(22):2435-42. PubMed ID: 24327038
[TBL] [Abstract][Full Text] [Related]
32. Association between proton pump inhibitor use and the risk of pancreatic cancer: A Korean nationwide cohort study.
Hwang IC; Chang J; Park SM
PLoS One; 2018; 13(9):e0203918. PubMed ID: 30208110
[TBL] [Abstract][Full Text] [Related]
33. Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study.
Wei J; Chan AT; Zeng C; Bai X; Lu N; Lei G; Zhang Y
Bone; 2020 Oct; 139():115502. PubMed ID: 32593677
[TBL] [Abstract][Full Text] [Related]
34. Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non-small-cell Lung Cancer.
Yokota H; Sato K; Okuda Y; Kobayashi H; Takeda M; Asano M; Ito H; Miura M
Clin Lung Cancer; 2017 Nov; 18(6):e433-e439. PubMed ID: 28579188
[TBL] [Abstract][Full Text] [Related]
35. Use of Proton Pump Inhibitors and the Risk of Listeriosis: A Nationwide Registry-based Case-Control Study.
Kvistholm Jensen A; Simonsen J; Ethelberg S
Clin Infect Dis; 2017 Apr; 64(7):845-851. PubMed ID: 28013257
[TBL] [Abstract][Full Text] [Related]
36. Comparative risk of Clostridium difficile infection between proton pump inhibitors and histamine-2 receptor antagonists: A 15-year hospital cohort study using a common data model.
Seo SI; You SC; Park CH; Kim TJ; Ko YS; Kim Y; Yoo JJ; Kim J; Shin WG
J Gastroenterol Hepatol; 2020 Aug; 35(8):1325-1330. PubMed ID: 31970824
[TBL] [Abstract][Full Text] [Related]
37. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.
Corley DA; Kubo A; Zhao W; Quesenberry C
Gastroenterology; 2010 Jul; 139(1):93-101. PubMed ID: 20353792
[TBL] [Abstract][Full Text] [Related]
38. Colorectal cancer risk in relation to use of acid suppressive medications.
Chubak J; Boudreau DM; Rulyak SJ; Mandelson MT
Pharmacoepidemiol Drug Saf; 2009 Jul; 18(7):540-4. PubMed ID: 19367565
[TBL] [Abstract][Full Text] [Related]
39. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies.
Eom CS; Park SM; Myung SK; Yun JM; Ahn JS
Ann Fam Med; 2011; 9(3):257-67. PubMed ID: 21555754
[TBL] [Abstract][Full Text] [Related]
40. Proton Pump Inhibitor Use and Risk of Developing Alzheimer's Disease or Vascular Dementia: A Case-Control Analysis.
Imfeld P; Bodmer M; Jick SS; Meier CR
Drug Saf; 2018 Dec; 41(12):1387-1396. PubMed ID: 30146658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
